Home Reports Chronic Granulomatous Disease (CGD) Management Market

Chronic Granulomatous Disease (CGD) Management Market

Chronic Granulomatous Disease (CGD) Management Market is segmented by Category (X-Linked Chronic Granulomatous Disease, Autosomal Recessive Chronic Granulomatous Disease), Diagnosis (Genetic Testing, Neutrophil Function Tests, Prenatal Testing), Treatment (Infection Management, Trimethoprim, Sulfamethoxazole, Itraconazole, Interferon-gamma, Stem Cell Transplantation, Others), and Region. Forecast for 2026 to 2036.

Historical Data Covered: 2016 to 2024 | Base Year: 2025 | Estimated Year: 2026 | Forecast Period: 2027 to 2036

Methodology

Chronic Granulomatous Disease (CGD) Management Market Size, Market Forecast and Outlook By FMI

Summary of the Chronic Granulomatous Disease (CGD) Management Market

  • Demand and Growth Drivers
    • Gene therapy advancement is creating potential curative treatment options for CGD.
    • Diagnostic improvements are enabling faster and more accurate disease identification.
    • Stem cell transplant access expansion is providing curative options for more patients.
  • Product and Segment View
    • X-linked CGD is expected to lead with 68.5% of category demand in 2026.
    • Genetic testing is expected to represent 42.7% of diagnostic demand.
    • Infection management is expected to account for 36.9% of treatment demand.
  • Geography and Competitive Outlook
    • The USA (4.8%) is expected to lead growth through immunology infrastructure and gene therapy development.
    • South Korea (4.6%) maintains strong growth through diagnostic capabilities and trial participation.
    • Companies with gene therapy pipelines and rare disease expertise are expected to drive treatment innovation.
  • Analyst Opinion
    • The CGD management market is evolving as gene therapy advances toward potential curative treatment.
    • Chronic prophylactic management remains the treatment foundation while curative approaches mature.
    • The market is benefiting from improving diagnostics and expanding stem cell transplant access.
    • Companies combining prophylactic treatment portfolios with gene therapy development are expected to capture emerging treatment value.

Chronic Granulomatous Disease (cgd) Management Market Value Analysis

Chronic Granulomatous Disease (CGD) Management Market Definition

The chronic granulomatous disease management market covers pharmaceutical, gene therapy, and supportive interventions used in managing CGD, a rare primary immunodeficiency characterized by defective phagocytic cells. Treatments include prophylactic antimicrobial therapy, interferon-gamma, hematopoietic stem cell transplantation, and emerging gene therapy approaches.

Chronic Granulomatous Disease (CGD) Management Market Inclusions

Market scope covers all commercially available CGD management products categorized by category (X-linked CGD, autosomal recessive CGD), diagnosis (genetic testing, dihydrorhodamine flow cytometry, nitroblue tetrazolium test, others), treatment (infection management, prophylactic therapy, stem cell transplantation, gene therapy, others), and end use (hospitals, specialty centres, homecare). Revenue coverage spans 2026 to 2036.

Chronic Granulomatous Disease (CGD) Management Market Exclusions

The scope does not include general immunology diagnostic panels, standard vaccination programs, or treatments for acquired immunodeficiency conditions.

Chronic Granulomatous Disease (CGD) Management Market Research Methodology

Primary Research: FMI analysts conducted interviews with immunologists, rare disease treatment specialists, and hospital pharmacy directors at immunodeficiency treatment centres.

Desk Research: Combined data from primary immunodeficiency registries, pharmaceutical prescription databases, and clinical trial registries.

Market Sizing and Forecasting: Bottom-up sizing across disease category, treatment modality, and end-use segments with regional immunodeficiency diagnosis rate curves.

Data Validation: Cross-checked quarterly against immunodeficiency registry data, pharmaceutical sales volumes, and gene therapy clinical trial updates.

Why is the Chronic Granulomatous Disease (CGD) Management Market Growing?

  • Advancing gene therapy approaches for CGD are creating potential curative treatment options that could reduce lifelong dependence on prophylactic antimicrobial therapy and interferon-gamma treatment.
  • Improving diagnostic capabilities including flow cytometry-based assays are increasing the speed and accuracy of CGD diagnosis, enabling earlier treatment initiation and prophylaxis.
  • Expansion of hematopoietic stem cell transplantation access and improved conditioning regimens are providing curative options for an increasing proportion of CGD patients with suitable donors.

Demand for CGD management reflects the chronic nature of the immunodeficiency and the lifelong treatment requirements for infection prevention and management. CGD affects approximately 1 in 200,000 to 250,000 individuals, with X-linked inheritance accounting for approximately 65 to 70% of cases. Prophylactic antimicrobial therapy and interferon-gamma form the foundation of chronic management.

Adoption of X-linked CGD management leads at 68.5% of category demand, reflecting the predominance of this inheritance pattern in the diagnosed patient population. X-linked CGD typically presents in early childhood with severe and recurrent infections, driving early treatment initiation and sustained pharmaceutical management.

Pricing reflects the combination of chronic prophylactic antimicrobial costs, interferon-gamma therapy, and the substantial expense of stem cell transplantation or gene therapy for eligible patients. The orphan disease status supports premium pricing for specialized therapies while government-funded rare disease programs provide access support.

Market Segmentation Analysis

  • X-Linked Chronic Granulomatous Disease accounts for 68.5% of the category segment.
  • Genetic Testing represents 42.7% of the diagnosis segment.
  • Infection Management leads the treatment segment with 36.9% share.

The chronic granulomatous disease (cgd) management market is segmented by category, diagnosis, treatment, and end use.

Insights into the X-Linked Chronic Granulomatous Disease Category Segment

Chronic Granulomatous Disease (cgd) Management Market Analysis By Category

X-linked CGD represents 68.5% of category demand due to its predominant inheritance pattern. Affecting males through mutations in the CYBB gene, X-linked CGD accounts for the majority of diagnosed cases and drives the largest proportion of chronic treatment demand.

Insights into the Genetic Testing Diagnosis Segment

Chronic Granulomatous Disease (cgd) Management Market Analysis By Diagnosis

Genetic testing represents 42.7% of diagnostic demand, reflecting its role as the definitive diagnostic method for confirming CGD and identifying the specific genetic mutation. Genetic confirmation supports treatment planning and family counseling.

Chronic Granulomatous Disease (CGD) Management Market Drivers, Restraints, and Opportunities

Chronic Granulomatous Disease (cgd) Management Market Opportunity Matrix Growth Vs Value

  • Regulatory and structural demand drivers are creating sustained procurement patterns.
  • Cost and access constraints create segmentation in adoption rates.
  • Technology and product development are expanding the addressable market.

The chronic granulomatous disease (cgd) management market is shaped by regulatory, technology, and procurement dynamics.

Gene Therapy Pipeline Advancement

Demand is shaped by advancing gene therapy programs that target correction of the underlying genetic defects in CGD. Successful gene therapy could provide functional cure, reducing lifelong dependence on prophylactic therapy.

Diagnostic Capability Improvement

Growth reflects improving flow cytometry and genetic testing capabilities that enable faster and more accurate CGD diagnosis. Earlier diagnosis supports timely prophylaxis initiation and improved clinical outcomes.

Stem Cell Transplant Access Expansion

Adoption of hematopoietic stem cell transplantation is increasing as improved conditioning regimens and donor matching expand the proportion of CGD patients eligible for curative transplant.

Chronic Management Cost Burden

Lifelong prophylactic therapy creates sustained pharmaceutical expenditure. The cost burden drives interest in curative approaches including gene therapy and stem cell transplantation that could reduce long-term treatment costs.

Analysis of Chronic Granulomatous Disease (CGD) Management Market By Key Countries

Top Country Growth Comparison Chronic Granulomatous Disease (cgd) Management Market Cagr (2026 2036)

Country CAGR
USA 4.8%
South Korea 4.6%
EU 4.4%
UK 4.2%
Japan 4.1%

Chronic Granulomatous Disease (cgd) Management Market Cagr Analysis By Country

  • USA leads with 4.8% CAGR.
  • South Korea at 4.6% reflects expanding capabilities.
  • EU (4.4%) and UK (4.2%) maintain steady growth.

The global chronic granulomatous disease (cgd) management market is expected to grow at 4.5% per year from 2026 to 2036.

Demand Outlook for Chronic Granulomatous Disease (CGD) Management Market in the United States

Chronic Granulomatous Disease (cgd) Management Market Country Value Analysis

The USA is expected to grow at 4.8% through 2036, driven by advanced immunology infrastructure, gene therapy clinical trial activity, and comprehensive insurance coverage for rare immunodeficiency treatment.

  • Immunology centres provide specialized CGD management.
  • Gene therapy trials offer potential curative approaches.
  • Insurance coverage supports chronic treatment costs.

Future Outlook for Chronic Granulomatous Disease (CGD) Management Market in South Korea

Chronic Granulomatous Disease (cgd) Management Market South Korea Market Share Analysis By Diagnosis

South Korea is expected to grow at 4.6% through 2036, supported by advanced genetic diagnostics, growing rare disease treatment infrastructure, and participation in multinational gene therapy trials.

  • Genetic diagnostics support accurate CGD identification.
  • Rare disease infrastructure investment expands treatment access.
  • Clinical trial participation advances treatment options.

Opportunity Analysis of Chronic Granulomatous Disease (CGD) Management Market in the European Union

Chronic Granulomatous Disease (cgd) Management Market Europe Country Market Share Analysis, 2026 & 2036

The EU is expected to grow at 4.5% through 2036, supported by EU rare disease treatment networks, immunology research investment, and cross-border specialist referral coordination.

  • EU rare disease networks coordinate specialist treatment.
  • Immunology research advances therapeutic options.
  • Cross-border referral improves access to expertise.

Sales Analysis of Chronic Granulomatous Disease (CGD) Management Market in the United Kingdom

The UK is expected to grow at 4.3% through 2036, supported by NHS specialist commissioning, immunology research centres, and genomic medicine integration for primary immunodeficiency diagnosis.

  • NHS specialist commissioning supports CGD treatment access.
  • Immunology research centres drive protocol improvement.
  • Genomic medicine improves diagnostic accuracy.

In-depth Analysis of Chronic Granulomatous Disease (CGD) Management Market in Japan

Chronic Granulomatous Disease (cgd) Management Market Japan Market Share Analysis By Category

Japan is expected to grow at 4.4% through 2036, driven by established immunology centres, government rare disease programs, and advanced diagnostic infrastructure.

  • Immunology centres provide comprehensive CGD care.
  • Government programs support rare disease treatment costs.
  • Diagnostic infrastructure enables early case identification.

Competitive Landscape and Strategic Positioning

Chronic Granulomatous Disease (cgd) Management Market Analysis By Company

  • Horizon Therapeutics leads with an estimated 14.2% market share.
  • The competitive landscape includes global and specialized players.
  • Entry barriers include regulatory, relationship, and scale factors.

Horizon Therapeutics leads through its rare disease pharmaceutical portfolio with products supporting primary immunodeficiency management.

Takeda Pharmaceutical and Orchard Therapeutics maintain positions through rare disease treatment programs and gene therapy development relevant to CGD.

AVROBIO, Inc. and Rocket Pharmaceuticals represent emerging gene therapy positions with investigational programs targeting CGD correction.

Entry barriers include rare disease clinical expertise, small patient populations, gene therapy development costs, and specialized immunology distribution requirements.

Key Companies in the Chronic Granulomatous Disease (CGD) Management Market

Key global companies leading the chronic granulomatous disease (cgd) management market include:

  • Horizon Therapeutics (USA), Takeda Pharmaceutical (Japan), and Orchard Therapeutics (UK) hold leading positions through rare disease portfolios and gene therapy programs.
  • AVROBIO, Inc. (USA) and Rocket Pharmaceuticals (USA) compete on gene therapy development targeting CGD genetic correction.
  • bluebird bio (USA), Mustang Bio (USA), and Genethon (France) represent additional gene therapy positions with primary immunodeficiency programs.

Competitive Benchmarking: Chronic Granulomatous Disease (CGD) Management Market

Company Rare Disease Portfolio Gene Therapy Pipeline Patient Access Programs Geographic Reach
Horizon Therapeutics High Low Strong N. America, Global
Takeda Pharmaceutical High Medium Strong Global
Orchard Therapeutics Low High Moderate Europe, N. America
AVROBIO, Inc. Low High Low N. America
Rocket Pharmaceuticals Low High Low N. America
Genethon Low High Low Europe

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Chronic Granulomatous Disease (CGD) Management Market

  • In 2025, Orchard Therapeutics advanced its gene therapy program for X-linked CGD with expanded clinical trial enrollment across European treatment centres.
  • In 2025, Rocket Pharmaceuticals reported positive interim data from its lentiviral gene therapy trial for X-linked CGD patients.

Key Players in the Chronic Granulomatous Disease (CGD) Management Market

Major Global Players

  • Horizon Therapeutics
  • Takeda Pharmaceutical
  • Orchard Therapeutics
  • AVROBIO, Inc.
  • Rocket Pharmaceuticals
  • Novartis AG
  • Regeneron Pharmaceuticals

Emerging Players/Startups

  • bluebird bio
  • Mustang Bio
  • Genethon
  • Editas Medicine
  • Sangamo Therapeutics

Report Scope and Coverage

Chronic Granulomatous Disease (cgd) Management Market Breakdown By Category, Diagnosis, And Region

Parameter Details
Quantitative Units USD 1.51 billion to USD 2.34 billion, at a CAGR of 4.5%
Market Definition The chronic granulomatous disease management market covers pharmaceutical, gene therapy, and supportive interventions used in managing CGD, a rare primary immunodeficiency characterized by defective phagocytic cells. Treatments include prophylactic antimicrobial therapy, interferon-gamma, hematopoietic stem cell transplantation, and emerging gene therapy approaches.
Regions Covered North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled Horizon Therapeutics, Takeda Pharmaceutical, Orchard Therapeutics, AVROBIO, Inc., Rocket Pharmaceuticals, Novartis AG, Regeneron Pharmaceuticals, CSL Behring, Gilead Sciences, Bluebird Bio
Forecast Period 2026 to 2036
Approach Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by Category:

  • X-Linked Chronic Granulomatous Disease
  • Autosomal Recessive Chronic Granulomatous Disease

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by Diagnosis:

  • Genetic Testing
  • Neutrophil Function Tests
  • Prenatal Testing

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by Treatment:

  • Infection Management
  • Trimethoprim
  • Sulfamethoxazole
  • Itraconazole
  • Interferon-gamma
  • Stem Cell Transplantation
  • Others

Chronic Granulomatous Disease (CGD) Management Market Market Segmented by End Use:

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Research Institutes

Chronic Granulomatous Disease (CGD) Management Market Market by Region:

  • North America
    • USA
    • Canada
    • Mexico
  • Latin America
    • Brazil
    • Chile
    • Rest of Latin America
  • Western Europe
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • Nordic
    • BENELUX
    • Rest of Western Europe
  • Eastern Europe
    • Russia
    • Poland
    • Hungary
    • Balkan & Baltic
    • Rest of Eastern Europe
  • East Asia
    • China
    • Japan
    • South Korea
  • South Asia and Pacific
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of South Asia and Pacific
  • Middle East & Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkiye
    • South Africa
    • Other African Union
    • Rest of Middle East & Africa

Research Sources and Bibliography

  • 1. Jeffrey Modell Foundation. (2025). JMF Primary Immunodeficiency Registry Report. JMF.
  • 2. European Society for Immunodeficiencies. (2024). ESID Clinical Practice Guidelines: CGD Management. ESID.
  • 3. National Institutes of Health. (2025). NIH National Institute of Allergy and Infectious Diseases: CGD Research. NIAID.
  • 4. USA Food and Drug Administration. (2025). FDA Gene Therapy Development for Primary Immunodeficiency. FDA.
  • 5. World Health Organization. (2024). WHO Classification of Primary Immunodeficiency Disorders. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

  • Estimating the market size and revenue from 2026 to 2036.
  • Segmentation by disease category, diagnosis, treatment, and end use.
  • Regional and country-level insights across more than 30 markets.
  • Gene therapy pipeline and clinical trial analysis.
  • Competitive landscape assessment.
  • Investment opportunity identification.
  • Diagnostic technology and treatment protocol analysis.
  • Data delivery in PDF and Excel formats.

Frequently Asked Questions

What is the global market demand for Chronic Granulomatous Disease (CGD) Management in 2026?

In 2026, the global market is expected to be worth USD 1.51 billion.

How big will the Chronic Granulomatous Disease (CGD) Management Market be in 2036?

By 2036, the market is expected to be worth USD 2.34 billion.

How much is demand expected to grow between 2026 and 2036?

Between 2026 and 2036, demand is expected to grow at a CAGR of 4.5%.

Which Category segment is expected to lead in 2026?

X-Linked Chronic Granulomatous Disease is expected to account for 68.5% of the segment in 2026.

What is causing demand to rise in USA?

USA is expected to grow at 4.8% through 2036.

What is causing demand to rise in South Korea?

South Korea is expected to grow at 4.6% through 2036.

What does this report mean by Chronic Granulomatous Disease (CGD) Management Market definition?

The chronic granulomatous disease management market covers pharmaceutical, gene therapy, and supportive interventions used in managing CGD, a rare primary immunodeficiency characterized by defective p.

How does FMI make the forecast?

Forecasting uses a hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Table of Content

  1. Executive Summary
    • Global Market Outlook
    • Demand to side Trends
    • Supply to side Trends
    • Technology Roadmap Analysis
    • Analysis and Recommendations
  2. Market Overview
    • Market Coverage / Taxonomy
    • Market Definition / Scope / Limitations
  3. Research Methodology
    • Chapter Orientation
    • Analytical Lens and Working Hypotheses
      • Market Structure, Signals, and Trend Drivers
      • Benchmarking and Cross-market Comparability
      • Market Sizing, Forecasting, and Opportunity Mapping
    • Research Design and Evidence Framework
      • Desk Research Programme (Secondary Evidence)
        • Company Annual and Sustainability Reports
        • Peer-reviewed Journals and Academic Literature
        • Corporate Websites, Product Literature, and Technical Notes
        • Earnings Decks and Investor Briefings
        • Statutory Filings and Regulatory Disclosures
        • Technical White Papers and Standards Notes
        • Trade Journals, Industry Magazines, and Analyst Briefs
        • Conference Proceedings, Webinars, and Seminar Materials
        • Government Statistics Portals and Public Data Releases
        • Press Releases and Reputable Media Coverage
        • Specialist Newsletters and Curated Briefings
        • Sector Databases and Reference Repositories
        • FMI Internal Proprietary Databases and Historical Market Datasets
        • Subscription Datasets and Paid Sources
        • Social Channels, Communities, and Digital Listening Inputs
        • Additional Desk Sources
      • Expert Input and Fieldwork (Primary Evidence)
        • Primary Modes
          • Qualitative Interviews and Expert Elicitation
          • Quantitative Surveys and Structured Data Capture
          • Blended Approach
        • Why Primary Evidence is Used
        • Field Techniques
          • Interviews
          • Surveys
          • Focus Groups
          • Observational and In-context Research
          • Social and Community Interactions
        • Stakeholder Universe Engaged
          • C-suite Leaders
          • Board Members
          • Presidents and Vice Presidents
          • R&D and Innovation Heads
          • Technical Specialists
          • Domain Subject-matter Experts
          • Scientists
          • Physicians and Other Healthcare Professionals
        • Governance, Ethics, and Data Stewardship
          • Research Ethics
          • Data Integrity and Handling
      • Tooling, Models, and Reference Databases
    • Data Engineering and Model Build
      • Data Acquisition and Ingestion
      • Cleaning, Normalisation, and Verification
      • Synthesis, Triangulation, and Analysis
    • Quality Assurance and Audit Trail
  4. Market Background
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunity
      • Trends
    • Scenario Forecast
      • Demand in Optimistic Scenario
      • Demand in Likely Scenario
      • Demand in Conservative Scenario
    • Opportunity Map Analysis
    • Product Life Cycle Analysis
    • Supply Chain Analysis
    • Investment Feasibility Matrix
    • Value Chain Analysis
    • PESTLE and Porter’s Analysis
    • Regulatory Landscape
    • Regional Parent Market Outlook
    • Production and Consumption Statistics
    • Import and Export Statistics
  5. Global Market Analysis 2021 to 2025 and Forecast, 2026 to 2036
    • Historical Market Size Value (USD Million) Analysis, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Projections, 2026 to 2036
      • Y to o to Y Growth Trend Analysis
      • Absolute $ Opportunity Analysis
  6. Global Market Pricing Analysis 2021 to 2025 and Forecast 2026 to 2036
  7. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Category
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Category , 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Category , 2026 to 2036
      • X-Linked Chronic Granulomatous Disease
      • Autosomal Recessive Chronic Granulomatous Disease
    • Y to o to Y Growth Trend Analysis By Category , 2021 to 2025
    • Absolute $ Opportunity Analysis By Category , 2026 to 2036
  8. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Diagnosis
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Diagnosis, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Diagnosis, 2026 to 2036
      • Genetic Testing
      • Neutrophil Function Tests
      • Prenatal Testing
    • Y to o to Y Growth Trend Analysis By Diagnosis, 2021 to 2025
    • Absolute $ Opportunity Analysis By Diagnosis, 2026 to 2036
  9. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Treatment
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By Treatment, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By Treatment, 2026 to 2036
      • Infection Management
      • Trimethoprim
      • Sulfamethoxazole
      • Itraconazole
      • Interferon-gamma
      • Stem Cell Transplantation
      • Others
    • Y to o to Y Growth Trend Analysis By Treatment, 2021 to 2025
    • Absolute $ Opportunity Analysis By Treatment, 2026 to 2036
  10. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By End Use
    • Introduction / Key Findings
    • Historical Market Size Value (USD Million) Analysis By End Use, 2021 to 2025
    • Current and Future Market Size Value (USD Million) Analysis and Forecast By End Use, 2026 to 2036
      • Hospitals
      • Specialty Clinics
      • Homecare Settings
      • Research Institutes
    • Y to o to Y Growth Trend Analysis By End Use, 2021 to 2025
    • Absolute $ Opportunity Analysis By End Use, 2026 to 2036
  11. Global Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Region
    • Introduction
    • Historical Market Size Value (USD Million) Analysis By Region, 2021 to 2025
    • Current Market Size Value (USD Million) Analysis and Forecast By Region, 2026 to 2036
      • North America
      • Latin America
      • Western Europe
      • Eastern Europe
      • East Asia
      • South Asia and Pacific
      • Middle East & Africa
    • Market Attractiveness Analysis By Region
  12. North America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • USA
        • Canada
        • Mexico
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Market Attractiveness Analysis
      • By Country
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Key Takeaways
  13. Latin America Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Brazil
        • Chile
        • Rest of Latin America
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Market Attractiveness Analysis
      • By Country
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Key Takeaways
  14. Western Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Germany
        • UK
        • Italy
        • Spain
        • France
        • Nordic
        • BENELUX
        • Rest of Western Europe
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Market Attractiveness Analysis
      • By Country
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Key Takeaways
  15. Eastern Europe Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Russia
        • Poland
        • Hungary
        • Balkan & Baltic
        • Rest of Eastern Europe
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Market Attractiveness Analysis
      • By Country
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Key Takeaways
  16. East Asia Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • China
        • Japan
        • South Korea
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Market Attractiveness Analysis
      • By Country
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Key Takeaways
  17. South Asia and Pacific Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • India
        • ASEAN
        • Australia & New Zealand
        • Rest of South Asia and Pacific
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Market Attractiveness Analysis
      • By Country
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Key Takeaways
  18. Middle East & Africa Market Analysis 2021 to 2025 and Forecast 2026 to 2036, By Country
    • Historical Market Size Value (USD Million) Trend Analysis By Market Taxonomy, 2021 to 2025
    • Market Size Value (USD Million) Forecast By Market Taxonomy, 2026 to 2036
      • By Country
        • Kingdom of Saudi Arabia
        • Other GCC Countries
        • Turkiye
        • South Africa
        • Other African Union
        • Rest of Middle East & Africa
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Market Attractiveness Analysis
      • By Country
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
    • Key Takeaways
  19. Key Countries Market Analysis
    • USA
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Canada
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Mexico
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Brazil
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Chile
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Germany
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • UK
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Italy
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Spain
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • France
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • India
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • ASEAN
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Australia & New Zealand
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • China
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Japan
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • South Korea
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Russia
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Poland
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Hungary
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Kingdom of Saudi Arabia
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • Turkiye
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
    • South Africa
      • Pricing Analysis
      • Market Share Analysis, 2025
        • By Category
        • By Diagnosis
        • By Treatment
        • By End Use
  20. Market Structure Analysis
    • Competition Dashboard
    • Competition Benchmarking
    • Market Share Analysis of Top Players
      • By Regional
      • By Category
      • By Diagnosis
      • By Treatment
      • By End Use
  21. Competition Analysis
    • Competition Deep Dive
      • Horizon Therapeutics
        • Overview
        • Product Portfolio
        • Profitability by Market Segments (Product/Age /Sales Channel/Region)
        • Sales Footprint
        • Strategy Overview
          • Marketing Strategy
          • Product Strategy
          • Channel Strategy
      • Takeda Pharmaceutical
      • Orchard Therapeutics
      • AVROBIO, Inc.
      • Rocket Pharmaceuticals
      • Novartis AG
      • Regeneron Pharmaceuticals
      • CSL Behring
      • Gilead Sciences
      • Bluebird Bio
  22. Assumptions & Acronyms Used

List of Tables

  • Table 1: Global Market Value (USD Million) Forecast by Region, 2021 to 2036
  • Table 2: Global Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 3: Global Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 4: Global Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 5: Global Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 6: North America Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 7: North America Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 8: North America Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 9: North America Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 10: North America Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 11: Latin America Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 12: Latin America Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 13: Latin America Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 14: Latin America Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 15: Latin America Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 16: Western Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 17: Western Europe Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 18: Western Europe Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 19: Western Europe Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 20: Western Europe Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 21: Eastern Europe Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 22: Eastern Europe Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 23: Eastern Europe Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 24: Eastern Europe Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 25: Eastern Europe Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 26: East Asia Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 27: East Asia Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 28: East Asia Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 29: East Asia Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 30: East Asia Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 31: South Asia and Pacific Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 32: South Asia and Pacific Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 33: South Asia and Pacific Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 34: South Asia and Pacific Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 35: South Asia and Pacific Market Value (USD Million) Forecast by End Use, 2021 to 2036
  • Table 36: Middle East & Africa Market Value (USD Million) Forecast by Country, 2021 to 2036
  • Table 37: Middle East & Africa Market Value (USD Million) Forecast by Category , 2021 to 2036
  • Table 38: Middle East & Africa Market Value (USD Million) Forecast by Diagnosis, 2021 to 2036
  • Table 39: Middle East & Africa Market Value (USD Million) Forecast by Treatment, 2021 to 2036
  • Table 40: Middle East & Africa Market Value (USD Million) Forecast by End Use, 2021 to 2036

List of Figures

  • Figure 1: Global Market Pricing Analysis
  • Figure 2: Global Market Value (USD Million) Forecast 2021-2036
  • Figure 3: Global Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 4: Global Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 5: Global Market Attractiveness Analysis by Category
  • Figure 6: Global Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 7: Global Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 8: Global Market Attractiveness Analysis by Diagnosis
  • Figure 9: Global Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 10: Global Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 11: Global Market Attractiveness Analysis by Treatment
  • Figure 12: Global Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 13: Global Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 14: Global Market Attractiveness Analysis by End Use
  • Figure 15: Global Market Value (USD Million) Share and BPS Analysis by Region, 2026 and 2036
  • Figure 16: Global Market Y-o-Y Growth Comparison by Region, 2026-2036
  • Figure 17: Global Market Attractiveness Analysis by Region
  • Figure 18: North America Market Incremental Dollar Opportunity, 2026-2036
  • Figure 19: Latin America Market Incremental Dollar Opportunity, 2026-2036
  • Figure 20: Western Europe Market Incremental Dollar Opportunity, 2026-2036
  • Figure 21: Eastern Europe Market Incremental Dollar Opportunity, 2026-2036
  • Figure 22: East Asia Market Incremental Dollar Opportunity, 2026-2036
  • Figure 23: South Asia and Pacific Market Incremental Dollar Opportunity, 2026-2036
  • Figure 24: Middle East & Africa Market Incremental Dollar Opportunity, 2026-2036
  • Figure 25: North America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 26: North America Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 27: North America Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 28: North America Market Attractiveness Analysis by Category
  • Figure 29: North America Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 30: North America Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 31: North America Market Attractiveness Analysis by Diagnosis
  • Figure 32: North America Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 33: North America Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 34: North America Market Attractiveness Analysis by Treatment
  • Figure 35: North America Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 36: North America Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 37: North America Market Attractiveness Analysis by End Use
  • Figure 38: Latin America Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 39: Latin America Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 40: Latin America Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 41: Latin America Market Attractiveness Analysis by Category
  • Figure 42: Latin America Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 43: Latin America Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 44: Latin America Market Attractiveness Analysis by Diagnosis
  • Figure 45: Latin America Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 46: Latin America Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 47: Latin America Market Attractiveness Analysis by Treatment
  • Figure 48: Latin America Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 49: Latin America Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 50: Latin America Market Attractiveness Analysis by End Use
  • Figure 51: Western Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 52: Western Europe Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 53: Western Europe Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 54: Western Europe Market Attractiveness Analysis by Category
  • Figure 55: Western Europe Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 56: Western Europe Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 57: Western Europe Market Attractiveness Analysis by Diagnosis
  • Figure 58: Western Europe Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 59: Western Europe Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 60: Western Europe Market Attractiveness Analysis by Treatment
  • Figure 61: Western Europe Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 62: Western Europe Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 63: Western Europe Market Attractiveness Analysis by End Use
  • Figure 64: Eastern Europe Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 65: Eastern Europe Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 66: Eastern Europe Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 67: Eastern Europe Market Attractiveness Analysis by Category
  • Figure 68: Eastern Europe Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 69: Eastern Europe Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 70: Eastern Europe Market Attractiveness Analysis by Diagnosis
  • Figure 71: Eastern Europe Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 72: Eastern Europe Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 73: Eastern Europe Market Attractiveness Analysis by Treatment
  • Figure 74: Eastern Europe Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 75: Eastern Europe Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 76: Eastern Europe Market Attractiveness Analysis by End Use
  • Figure 77: East Asia Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 78: East Asia Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 79: East Asia Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 80: East Asia Market Attractiveness Analysis by Category
  • Figure 81: East Asia Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 82: East Asia Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 83: East Asia Market Attractiveness Analysis by Diagnosis
  • Figure 84: East Asia Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 85: East Asia Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 86: East Asia Market Attractiveness Analysis by Treatment
  • Figure 87: East Asia Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 88: East Asia Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 89: East Asia Market Attractiveness Analysis by End Use
  • Figure 90: South Asia and Pacific Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 91: South Asia and Pacific Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 92: South Asia and Pacific Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 93: South Asia and Pacific Market Attractiveness Analysis by Category
  • Figure 94: South Asia and Pacific Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 95: South Asia and Pacific Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 96: South Asia and Pacific Market Attractiveness Analysis by Diagnosis
  • Figure 97: South Asia and Pacific Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 98: South Asia and Pacific Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 99: South Asia and Pacific Market Attractiveness Analysis by Treatment
  • Figure 100: South Asia and Pacific Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 101: South Asia and Pacific Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 102: South Asia and Pacific Market Attractiveness Analysis by End Use
  • Figure 103: Middle East & Africa Market Value Share and BPS Analysis by Country, 2026 and 2036
  • Figure 104: Middle East & Africa Market Value Share and BPS Analysis by Category , 2026 and 2036
  • Figure 105: Middle East & Africa Market Y-o-Y Growth Comparison by Category , 2026-2036
  • Figure 106: Middle East & Africa Market Attractiveness Analysis by Category
  • Figure 107: Middle East & Africa Market Value Share and BPS Analysis by Diagnosis, 2026 and 2036
  • Figure 108: Middle East & Africa Market Y-o-Y Growth Comparison by Diagnosis, 2026-2036
  • Figure 109: Middle East & Africa Market Attractiveness Analysis by Diagnosis
  • Figure 110: Middle East & Africa Market Value Share and BPS Analysis by Treatment, 2026 and 2036
  • Figure 111: Middle East & Africa Market Y-o-Y Growth Comparison by Treatment, 2026-2036
  • Figure 112: Middle East & Africa Market Attractiveness Analysis by Treatment
  • Figure 113: Middle East & Africa Market Value Share and BPS Analysis by End Use, 2026 and 2036
  • Figure 114: Middle East & Africa Market Y-o-Y Growth Comparison by End Use, 2026-2036
  • Figure 115: Middle East & Africa Market Attractiveness Analysis by End Use
  • Figure 116: Global Market - Tier Structure Analysis
  • Figure 117: Global Market - Company Share Analysis